Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Byron Vaughn MD, MS, AGAF, FCCF

Byron P. Vaughn MD, MS, AGAF, FCCF

Associate Professor of Medicine; Co-Director, Inflammatory Bowel Disease Program, Division of Gastroenterology Hepatology and Nutrition, University of Minnesota, Minneapolis, Minnesota

Dr. Vaughn is an Associate Professor of Medicine and Co-Director of the Inflammatory Bowel Disease Program at the University of Minnesota. His research focuses on microbiota therapeutics for inflammatory bowel disease and C. difficile infection.

Disclosures

Dr. Vaughn reports the following:
  • Grant support from Roche, Takeda, Nestle, KateFarms, Diasorin
  • Consulting: HealthDelegates 

Recent Contributions to PracticeUpdate:

  1. Safety and Tolerability of CP101 for the Prevention of Recurrent Clostridioides difficile Infection
  2. Ulcerative Colitis: Supplemental Bifid Triple Viable Capsule Treatment Improves Inflammatory Response
  3. IBD Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile
  4. Recurrence of C. difficile Infection in Patients With IBD

Most Read This Week

Recently Updated